MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
c-Met Proto-oncogene | Targeting Overexpression
Overcoming therapy resistance in EGFR-mutant lung cancer | Nature Cancer
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
The multiple paths towards MET receptor addiction in cancer | Oncogene
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis - The American Journal of Pathology
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
Targeting un-MET needs in advanced non-small cell lung cancer - ScienceDirect
Biomarkers in Lung Cancer: Integration with Radiogenomics Data | IntechOpen
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients - Annals of Oncology
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
MET and TP 53: How They Relate to ALK Lung Cancer — ALK POSITIVE
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
